泰格醫藥(03347.HK)全資子公司購買日本MICRON部分股權
格隆匯7月28日丨泰格醫藥(03347.HK)公吿,公司全資附屬公司株式會社泰格醫藥日本("日本泰格")與日本MICRON╱株式會社マイクロン("MICRON")原股東簽署《股份轉讓協議》購買其持有的部分MICRON股權,本次轉讓完成後,日本泰格將持有MICRON 56.37%股權。
MICRON成立於2005年,總部位於日本東京,員工人數超過160人,是一家專注於醫學影像及臨牀試驗服務的CRO公司。作為日本首家專注影像分析的CRO,MICRON以其卓越的技術能力及在影像生物標誌物、AI影像支持等方面的獨特實踐,在日本臨牀研究領域樹立了良好口碑,贏得了客户的長期信賴和讚譽,並在2024年入圍全日本最佳合同研究組織獎。憑藉其在臨牀研究領域的豐富經驗和亞洲規模最大的影像專業團隊之 一,在近20年的發展過程中為超過250個客户提供相關服務,並助力超過40款產品成功上市。
MICRON核心業務為影像分析業務,其主要客户為日本本土以及國外醫藥企業;另有部分其他相關業務,如臨牀監查業務,臨牀試驗PM相關服務,提供醫療影像診斷軟件(SaMD)的全生命週期服務應用,器械銷售等業務。
本次交易完成後,藉助MICRON在日本市場的深厚根基與客户資源,有利於公司進一步深度拓展在日本及亞太的業務佈局;同時,雙方可以實現技術與人才深度融合,增強在醫學影像和臨牀服務領域的綜合競爭力,對公司未來經營產生積極影響,符合公司全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.